(All fields required)
Please enter a valid email.
Please enter your name.
Showing 1 - 8 of 8 records.
The purpose of this research study is to find out if urine obtained from patients who are undergoing a blood or marrow transplant, contains proteins that can help predict if the kidneys have been injured. Kidneys can be injured from the chemotherapy, from infections, and/or from other medications u...More
Cincinnati Children’s is conducting a research study to evaluate the safety and effectiveness of a treatment regimen combining two previous approaches to treat patients with HLH....More
The purpose of this protocol is to find the biochemical and genetic causes of inherited immune diseases affecting lymphocytes. A second purpose is to develop new knowledge which will help research doctors find better ways to prevent, diagnosis, and treat these inherited immune diseases. ...More
The purpose of this research study is to help investigators learn more about Fanconi anemia. ...More
Shwachman-Diamond syndrome (SDS) is a rare condition which is usually diagnosed in infancy or early childhood. It can affect a wide range of organs but most commonly the digestion and the blood system are involved. Bone abnormalities and poor growth are also often seen in SDS patients. Researchers ...More
The purpose of this research study is to learn more about the cause and outcome for Severe Chronic Neutropenia (SCN). The objective of the Registry is to collect information on the natural course of SCN and its response to treatment with the blood stimulating factor called granulocyte colony stimul...More
The purpose of this research study is to help the doctors learn more about disorders of the immune system. The research doctors of the Cancer and Blood Diseases Institute at Cincinnati Children's Hospital Medical Center would like to collect blood / tissue samples from patients with a diagnosis or ...More
Cincinnati Children’s is participating in a research study sponsored by
NovImmune S.A. to evaluate the safety, tolerability and preliminary efficacy of
a new drug (NI-0501) aimed at controlling disease activity in patients
diagnosed with primary hemophagocytic lymphohistiocytosis who show an
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026 | 1-513-636-4200 | 1-800-344-2462 | TTY: 1-513-636-4900
New to Cincinnati Children’s or live outside of the Tristate area? 1-877-881-8479
© 1999-2014 Cincinnati Children's Hospital Medical Center